Le Lézard
Classified in: Health
Subjects: HEALTH, ANALYSTS' COMMENTS, MISCELLANEOUS, MISCELLANEOUS, ECONOMIC NEWS/TRENDS/ANALYSIS

New Frontier Data Projects Annual U.S. Cannabis Sales to More Than Double to $72B by 2030


Washington, March 23, 2022 (GLOBE NEWSWIRE) -- New Frontier Data (https://newfrontierdata.com), the premier data, analytics and technology firm specializing in the global cannabis industry, in partnership with FTI Consulting, releases its annual market update, the 2022 U.S. Cannabis Report: Industry Projections & Trends, which provides expert analysis of the drivers shaping the U.S. cannabis economy including potential state market activations, consumption trends, product innovation and sustainability efforts. 

The report projects annual U.S. legal cannabis sales to exceed $57 billion by 2030 (a CAGR of 14%) in current legal states, and if the 18 additional state markets poised to legalize activate, this figure would top $72 billion. Overall growth is fueled by convergent forces including strong consumer demand and an influx of newly operational legal state markets in recent years. Additionally, more adults are consuming cannabis regularly amid normalization and increasing societal recognition of the plant's therapeutic and wellness applications. 

"The seismic shift in public perception around cannabis is fueled in part by the growing exposure that Americans have through legal, regulated markets," said Gary Allen, New Frontier Data's CEO. "Even in the absence of a federal framework, the resilience and growth potential of a determined industry is laying the foundation for a safe and sustainable consumer category." 

Other Key Findings: 

Download a complimentary copy of 2022 U.S. Cannabis Report: Industry Projections & Trends: https://info.newfrontierdata.com/us-cannabis-2022.

 About New Frontier Data:

New Frontier Data is the premier data, analytics and technology firm specializing in the global cannabis industry, delivering solutions that enable investors, operators, advertisers, brands, researchers and policy makers to assess, understand, engage and transact with the cannabis industry and its consumers.

Our mission is to inform policy and commercial activity for the global legal cannabis industry. We maintain a neutral position on the merits of cannabis legalization through comprehensive and transparent data analysis and projections that shape industry trends, dynamics, demand and opportunity drivers. Founded in 2014, New Frontier Data is headquartered in Washington, D.C. with a presence in Europe, Latin America and Africa. For more information about New Frontier Data, please visit us at https//www.NewFrontierData.com.

Attachment



These press releases may also interest you

at 03:14
Caliway Biopharmaceuticals (Caliway) is pleased to announce its participation to share the latest clinical advancements at the upcoming 2024 BIO International Convention on Wednesday, June 5th, at 11:45 a.m. PDT. The presentation will take place in...

10 mai 2024
On May 10, 2024, the impactful international academic journal, Science Immunology, a sub-journal of Science, published a research paper titled "Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system...

10 mai 2024
Fitness International, LLC opened a new Club Studio location in Kingwood, Texas. The new 40,000 square foot club features five innovative boutique fitness studios that were carefully curated to create a unique experience, along with recovery services...

10 mai 2024
Mirum Pharmaceuticals, Inc. today announced that on May 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 38,600 shares of common stock and 19,300...

10 mai 2024
Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759...

10 mai 2024
Inhibrx, Inc. ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. ("SpinCo") to holders of shares of...



News published on and distributed by: